Tocilizumab can block the IL-6–IL-6R pathway by binding to IL-6R and has been approved to treat different types of arthritis. A phase II trial (NCT03004703) showed its ability to reduce hsCRP in the patients with NSTEMI. It also improved myocardial salvage index and facilitated hsCRP reduction in the patients with STEMI. This evidence concerns the gene IL6 and arthritic joint disease.